NCT07020468View on ClinicalTrials.gov

Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

July 30, 2025

Study Completion Date

May 31, 2027

Conditions
Colorectal Cancer (CRC)
Interventions
DRUG

NALIRIFOX

The patients with Locally Advanced Colorectal Cancer and Upper Rectal Cancer will undergo neoadjuvant treatment with irinotecan liposome combined with oxaliplatin + 5-FU/LV (NALIRIFOX), with each treatment cycle lasting 2 weeks, for a total of 3-6 cycles.

Trial Locations (1)

515000

Cancer Hospital of Shantou University Medical College, Shantou

All Listed Sponsors
lead

Affiliated Cancer Hospital of Shantou University Medical College

OTHER